Target intelligence / Profile preview

Nucleobindin-1 (NUCB1)

Target
NUCB1
Molecular classification
Other (multidomain calcium-binding protein), Chaperone-like amyloid binding protein (CLABP), Guanine nucleotide dissociation inhibitor (GDI) for G proteins
01

Overview

Nucleobindin-1 (NUCB1) is a multidomain calcium-binding protein featuring two EF-hand motifs, a leucine zipper, a DNA-binding region, and a nuclear localization signal[1][3][5][6]. NUCB1 is found in the Golgi apparatus, ER, nucleus, and cytoplasm, where it acts as a calcium sensor, participates in protein trafficking, and regulates signaling pathways—including functioning as a calcium-dependent guanine nucleotide dissociation inhibitor for Gαi subunits of heterotrimeric G proteins[1][3]. NUCB1 also binds to protofibrillar amyloid aggregates from proteins such as Aβ42, α-synuclein, islet amyloid polypeptide, and transthyretin, stabilizing their soluble intermediates and preventing toxic fibril formation—which implicates NUCB1 in neurodegenerative and metabolic diseases as a natural chaperone-like amyloid binding protein[2][3]. In the ER and Golgi, NUCB1 negatively regulates the unfolded protein response, impacting cellular stress reactions[3]. Its structure and multiple interaction domains enable both nucleic acid and protein binding, with emerging evidence of enzymatic activities (e.g., serine protease-like) regulated by interactions with metal ions and G proteins[3][4][6].

Other names
CalnucNUCnucleobindin-1
02

Mechanism of action

N/A—no drugs act directly on NUCB1. Its actions involve protein-protein interactions, inhibitory capping of amyloid protofibrils, and regulation of nucleotide release from Gαi subunits[1][2].

03

Biological functions

Calcium bindingDNA bindingProtein-protein interactionsRegulation of G protein signaling (as a Ca²⁺-dependent GDI)Negative feedback of unfolded protein response (UPR)Protein trafficking (notably Golgi-based trafficking of MMPs)Chaperone-like inhibition of amyloid fibril aggregation
04

Disease associations

Neurodegenerative disease (amyloid regulation: Alzheimer’s, Parkinson’s)Type 2 diabetes mellitus (islet amyloid polypeptide aggregation)Familial amyloid polyneuropathy (transthyretin aggregation)Cancer (roles in cell signaling and protein homeostasis)Lupus/autoimmunity (early association with B cell differentiation)

Beyond the preview

Go deeper on Nucleobindin-1 (NUCB1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nucleobindin-1 (NUCB1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call